MiR‐4485‐3p expression reduced in spermatozoa of men with idiopathic asthenozoospermia

Heidary, Zohreh; Zaki‐Dizaji, Majid; Saliminejad, Kioomars; Edalatkhah, Haleh; Khorshid, Hamid Reza Khorram

doi:10.1111/and.13539

Cited by 14 publications

(10 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In patients with asthenozoospermia, characterized by a reduction in sperm motility, the relative content of PARK7 is lower in both ejaculated sperm [ 19 , 24 ] and seminal plasma [ 25 ]. In addition, PARK7 has been identified as a target of miR-4485-3, whose downregulation has also been associated to asthenozoospermia [ 26 ]. Under oxidative stress conditions associated with asthenozoospermia, PARK7 has been observed to be translocated from the equatorial segment to the midpiece, which has been proposed as a possible protective mechanism for sperm to maintain their mitochondrial function [ 20 ].…”

Section: Introductionmentioning

confidence: 99%

Parkinson Disease Protein 7 (PARK7) Is Related to the Ability of Mammalian Sperm to Undergo In Vitro Capacitation

Recuero

Delgado-Bermúdez

Mateo‐Otero

et al. 2021

IJMS

View full text Add to dashboard Cite

Parkinson disease protein 7 (PARK7) is a multifunctional protein known to be involved in the regulation of sperm motility, mitochondrial function, and oxidative stress response in mammalian sperm. While ROS generation is needed to activate the downstream signaling pathways required for sperm to undergo capacitation, oxidative stress has detrimental effects for sperm cells and a precise balance between ROS levels and antioxidant activity is needed. Considering the putative antioxidant role of PARK7, the present work sought to determine whether this protein is related to the sperm ability to withstand in vitro capacitation. To this end, and using the pig as a model, semen samples were incubated in capacitation medium for 300 min; the acrosomal exocytosis was triggered by the addition of progesterone after 240 min of incubation. At each relevant time point (0, 120, 240, 250, and 300 min), sperm motility, acrosome and plasma membrane integrity, membrane lipid disorder, mitochondrial membrane potential, intracellular calcium and ROS were evaluated. In addition, localization and protein levels of PARK7 were also assessed through immunofluorescence and immunoblotting. Based on the relative content of PARK7, two groups of samples were set. As early as 120 min of incubation, sperm samples with larger PARK7 content showed higher percentages of viable and acrosome-intact sperm, lipid disorder and superoxide levels, and lower intracellular calcium levels when compared to sperm samples with lower PARK7. These data suggest that PARK7 could play a role in preventing sperm from undergoing premature capacitation, maintaining sperm viability and providing a better ability to keep ROS homeostasis, which is needed to elicit sperm capacitation. Further studies are required to elucidate the antioxidant properties of PARK7 during in vitro capacitation and acrosomal exocytosis of mammalian sperm, and the relationship between PARK7 and sperm motility.

show abstract

Section: Introductionmentioning

confidence: 99%

Parkinson Disease Protein 7 (PARK7) Is Related to the Ability of Mammalian Sperm to Undergo In Vitro Capacitation

Recuero

Delgado-Bermúdez

Mateo‐Otero

et al. 2021

IJMS

View full text Add to dashboard Cite

show abstract

“…Another study on mitochondrial microRNAs demonstrated that miR‐4485‐3p expression level was reduced in semen samples of asthenozoospermic patients compared with fertile men. They also found that the dynein heavy chain 1 gene (DNAH1), KIT and parkinsonism‐associated deglycase (PARK7), regulated by miR‐4485‐3p, were associated with male infertility (Heidary et al, 2020).…”

Section: Resultsmentioning

confidence: 99%

Using microRNAs as molecular biomarkers for the evaluation of male infertility

Asadpour

Chelan

2021

Andrologia

View full text Add to dashboard Cite

Infertility is a multiplex disorder in the reproductive system, and men are responsible for more than half of the cases. Nowadays, semen analysis has been considered the critical assessment test to diagnose infertile men; however, it has limitations so that the cause behind infertility in 40% of infertile men is unrevealed. Weaknesses of semen assessment indicate a global need for novel and better diagnostic tools and biomarkers. MicroRNAs are short (about 18–22 nucleotide length) non‐coding RNAs that control most (>60%) of our protein‐coding genes post‐transcriptionally. These molecules are aberrant in the body fluids, and abnormal alterations in their expression level can signify a specific disease such as infertility. Therefore, microRNAs can be novel candidate biomarkers that can diagnose different types of male infertility, including azoospermia, oligozoospermia, asthenozoospermia and teratozoospermia. This narrative review aimed to collect and sum up new papers published about the significant role of microRNAs in different male infertility categories.

show abstract

“…BDNF was detected in the head, neck, and tail of human spermatozoa [36], and exogenous BDNF at 0.133 nM could signi cantly in uence viability and motility of human sperm [37]. The expression of miR-4485 was signi cantly downregulated in the asthenozoospermia patients compared to controls, and KIT, which acts as its target gene, was related to male infertility by bioinformatic analysis [38]. These hub genes enriched in neurotrophin signaling pathway, indicating that they were critical for differentiation of nerve cells as well as playing critical roles in the development of reproductive system and the maintenance of spermatozoa normal function.…”

Section: Discussionmentioning

confidence: 97%

Screening, Identification and Interaction Analysis of Key MicroRNAs and Genes in Asthenozoospermia

Chen

2020

Preprint

View full text Add to dashboard Cite

Background: Asthenozoospermia, one of the most common causes of male infertility, is a complicate multifactorial pathological condition that genetic factors are involved in. However, the epigenetic signature and mechanism of asthenozoospermia still remain limited. Our study aimed to confirm the key microRNAs (miRNAs) and genes in asthenozoospermia and demonstrate the underlying epigenetic regulatory mechanisms. Methods: We screened out and pooled previous studies to extracted potential differentially expressed miRNAs (DEMs). GSE22331 and a published profile dataset were integrated to identify differentially expressed genes (DEGs). Pathway and gene ontology analysis were performed using DAVID. A protein-protein network (PPI) was constructed using STRING. The target genes of DEMs were predicted using TargetScan and then built the miRNA-mRNA network.Results: We reported 3 DEMs and 423 DEGs by pooling included dataset and published studies. Pathway analysis showed that these DEGs might participate in signaling pathways regulating pluripotency of stem cells, wnt signaling pathway and notch signaling pathway. 25 hub genes were identified, and the most significant gene was BDNF. We screened out the overlapped DEGs between the predicted target genes of 3 DEMs and the 423 DEGs. Then we constructed miRNA-mRNA network. Conclusion: This study firstly pooled several published studies and a GEO dataset to determine the significance of potential miRNAs and genes, such as miR-374b, miR-193a, miR-34b, BDNF, NTRK2, HNRNPD and EFTUD2 in regulating asthenozoospermia and underscore their interactions in the pathophysiological mechanism. Our results provided theoretical basis and new clues for potential therapeutic treatment in asthenozoospermia. Validations in vivo and in vitro are required in future studies.

show abstract

MiR‐4485‐3p expression reduced in spermatozoa of men with idiopathic asthenozoospermia

Cited by 14 publications

References 56 publications

Parkinson Disease Protein 7 (PARK7) Is Related to the Ability of Mammalian Sperm to Undergo In Vitro Capacitation

Parkinson Disease Protein 7 (PARK7) Is Related to the Ability of Mammalian Sperm to Undergo In Vitro Capacitation

Using microRNAs as molecular biomarkers for the evaluation of male infertility

Screening, Identification and Interaction Analysis of Key MicroRNAs and Genes in Asthenozoospermia

Contact Info

Product

Resources

About